The many faces of EMMPRIN—Roles in neuroinflammation  by Agrawal, Smriti M. & Yong, V. Wee
Biochimica et Biophysica Acta 1812 (2011) 213–219
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbad isThe many faces of EMMPRIN—Roles in neuroinﬂammation
Smriti M. Agrawal, V. Wee Yong ⁎
Hotchkiss Brain Institute and the Departments of Clinical Neurosciences and Oncology, University of Calgary, Calgary, Alberta, Canada⁎ Corresponding author. University of Calgary, 3330
Alberta, Canada T2N 4N1. Tel.: +1 403 220 3544; fax: +
E-mail address: vyong@ucalgary.ca (V.W. Yong).
0925-4439/$ – see front matter © 2010 Elsevier B.V. Al
doi:10.1016/j.bbadis.2010.07.018a b s t r a c ta r t i c l e i n f oArticle history:
Received 8 December 2009
Received in revised form 7 July 2010
Accepted 26 July 2010




Central nervous system disease
Multiple SclerosisThe central nervous system (CNS) is a relatively immune-privileged organ, wherein a well-instated barrier
system (the blood–brain barrier) prevents the entry of blood cells into the brain with the exception of
regular immune surveillance cells. Despite this tight security immune cells are successful in entering the CNS
tissue where they result in states of neuroinﬂammation, tissue damage and cell death. Various components
of the blood–brain barrier and inﬁltrating cells have been examined to better understand how blood cells are
able to breach this secure barrier. Proteases, speciﬁcally matrix metalloproteinases (MMP), have been found
to be the common culprits in most diseases involving neuroinﬂammation. MMPs secreted by inﬁltrating cells
act speciﬁcally upon targets on various components of the blood–brain barrier, compromising this barrier
and allowing cell inﬁltration into the CNS. Extracellular matrix metalloproteinase inducer (EMMPRIN) is an
upstream inducer of several MMPs and is suggested to be the master regulator of MMP production in disease
states such as cancer metastasis. EMMPRIN in the context of the CNS is still relatively understudied. In this
review we will introduce EMMPRIN, discuss its ligands and roles in non-CNS conditions that can help
implicate its involvement in CNS disorders, showcase its expression within the CNS in healthy and disease
conditions, elucidate its ligands and receptors, and brieﬂy discuss the emerging roles it plays in various
diseases of the CNS involving inﬂammation.Hospital Drive N.W. Calgary,
1 403 210 8840.
l rights reserved.© 2010 Elsevier B.V. All rights reserved.EMMPRIN (CD147) is a member of the immunoglobulin (Ig) super
family, comprised of two Ig-like domains which have a strong
homology with both Ig Vκ domain and the β-chain of the major
histocompatibility complex (MHC) class II antigen (Fig. 1). It is a cell
surface glycoprotein expressed on numerous cell types [1–4]. Originally
identiﬁed in lung carcinoma cells as a secreted factor capable of
stimulating collagenase activity in human ﬁbroblasts, EMMPRIN has
been identiﬁed independently in several different model systems
resulting in a long list of acronyms for this molecule including tumor
collagenase stimulatory factor (TCSF) [5]), M6 (Human) [3], Neurothe-
lin, 5A11 andHT7 (chicken) [6–8], OX47 and CE9 (rat) [1,9], and basigin
and gp42 (human and mouse) [2,10]. EMMPRIN was most recently
shown to induce the production of several MMPs, resulting in its
renaming to extracellular matrix metalloproteinase inducer, EMMPRIN
[4,11].
1. EMMPRIN structure and homology
The full-length human EMMPRIN is comprised of 269 amino acid
residues, wherein positions 25 to 200 on the protein sequence comprise
the extracellular domain; 77 residues from position 25 to 101 are the
extracellular Ig-like domain I (ECI); and 95 residues from position 106to 200 are the extracellular Ig-like domain II (ECII) [2,12] (Fig. 1). The
extracellular region contains three N-linked glycosylation sites,
associated with 5–35 kDa glycosylation (glycan) content [4,13]. The
MMP induction site has been identiﬁed on the ECI domain of EMMPRIN
and N-glycosylation at the Asn site (residue 44 in both mouse and
human) of this domain is considered crucial in the MMP-stimulating
activity [4,11,14] (Fig. 1). The single transmembrane domain sequence
is completely conserved among species, and the presence of a charged
residue, glutamic acid, in the middle of this domain suggests possible
association of this molecule with other transmembrane proteins [2,15].
Human EMMPRIN is expressed as two differentially spiced isoforms
and is characterized by the presence of two extracellular immunoglob-
ulin-like domains, and a single transmembrane domain possessing a
charged amino acid and a short cytoplasmic tail [1]. A recently
discovered retina speciﬁc isoformwith 3 Ig domains has been renamed
basigin-1, and the prototypical isoform, possessing two immunoglob-
ulin domains, has been renamed basigin-2 [16,17]. Both isoforms are
variably glycosylated, resulting in signiﬁcant alterations in EMMPRIN
function and protein interactions. A 22-kDa active form of EMMPRIN is
shed from cell surfaces by MMP-14 and secreted [18].
2. CNS tissue and cellular distribution of EMMPRIN in
development and adult
EMMPRIN (identiﬁed as neurothelin) is present on chicken
endothelial cells at the blood–brain barrier and also on pigment
Fig. 1. Schematic of EMMPRIN structure and functions attributed to its various domains.
EMMPRIN is composed of two extracellular domains (EC1 and EC2), a transmembrane
domain (TD), and a cytoplasmic domain (CD). Each EC loop is hinged by disulphide
bonds (s―s), and made up of a speciﬁc number of amino acids (a.a). Sites of
glycosylation are marked by curved lines on EC1. Speciﬁc sites are reserved on the
EMMPRIN molecule for binding with various ligands; these are represented for each
domain. Abbreviations: a.a.—amino acid; MCT-1—monocarboxylate transporter-1.
Adapted from [85].
Fig. 2. Mechanisms by which EMMPRIN mediate invasiveness of cancer cells.
Membrane associated EMMPRIN expressed on tumor cells binds homotypically with
EMMPRIN on stromal cells, or through soluble EMMPRIN, causes the release of MMPs
that facilitate tumor invasiveness. Adapted from Ref. [13].
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development, EMMPRIN is expressed in neuroblasts, but disappears
from neurons upon differentiation, becoming restricted to capillary
endothelial cells in the adult brain [19,20]. In contrast to chicken, in
mouse and rat, EMMPRIN is differentially expressed in various sub-
regions of the CNS suggesting that in mammals EMMPRIN has diverse
functions other than contributions to the blood–brain barrier
[10,21,22]. EMMPRIN expression has been reported in the olfactory
system, hippocampal formation, septal area, amygdala, thalamic
anterior nuclei, hypothalamus, mesencephalic tegmentum, entorhinal
cortex, and cingulate gyrus EMMPRIN is also expressed in the retinal
neuronal layers, the Vth layer of the cerebral neocortex, Purkinje cells
of the cerebellum, several nuclei of the brain stem, and the gray
matter of the spinal cord [22].
In adult mammalian CNS, EMMPRIN is thought to inﬂuence
synapse formation [23], neuron–glial interactions [24,25] as well
augments the outgrowth of astrocyte processes. Astrocytes represent
an important lactate source for neurons. They constitutively exhibit a
high glycolytic rate and release large amounts of lactate [26].
Monocarboxylate transporters (MCTs) are involved in mediating
lactate transport and three MCT subtypes have been described on
astrocytes [27]. Two members of the MCT family of proteins, MCT1
and MCT4, are found to use EMMPRIN as a chaperone for their
expression at the plasma membrane [28]; in this manner, the
association of MCT with EMMPRIN is thought to affect development
of neuron–glial interactions in the drosophila retina [25].
3. Roles of EMMPRIN, ligands and receptors: lessons from
non-CNS systems
Early observations of EMMPRIN expression in tumors have shed
light on its role as an MMP inducer. EMMPRIN was initially identiﬁed
following the result that interstitial collagenase (MMP-1) production
was induced during the co-culturing of tumor cells and ﬁbroblasts
[29,30]. Further studies revealed that EMMPRIN was capable of
inducing the expression of several other MMPs, including MMP-2,
MMP-3,MMP-9 andMMP-11 [4,11,31,32]. It was also determined that
either EMMPRIN expressing tumor cells or conditioned media fromthe same cells were equally capable of inducing MMP production in
co-cultured ﬁbroblast cells [29,30] (Fig. 2), indicating that both
membrane bound and soluble EMMPRIN are equally capable of
inducing MMP production [18,33–35]. It has also been determined
that EMMPRIN, similar to other Ig containing molecules, interacts
homotypically, and that this homotypic interaction, and its N-linked
glycosylation, are both crucial for its role as an MMP inducer [31].
The signaling pathway used by EMMPRIN to stimulate MMPs is
poorly understood. Previous studies reported that EMMPRIN stimu-
lates MMP-1 or -2 using the p38 MAPK pathway [36], but stimulates
MMP production in breast cancer cells using the phospholipase A2 and
5-lipoxgenase pathways [37]. Another potential signaling pathway
may involve ErbB2.
Although an EMMPRIN speciﬁc receptor has not yet been identiﬁed,
and besides the homotypic binding of EMMPRIN noted above,
immunoprecipitation and immunoﬂuorescence co-localisation experi-
ments have identiﬁed two integrins (α3β1 and α6β that associate
with EMMPRIN at points of cell-cell contact [38] (Fig. 1). These
integrins, which are shown to preferentially bind to laminins that serve
as the major constituents of the basement membrane, have been
implicated in cell adhesion, metastasis and signaling. Through the
association of EMMPRINwith integrin, it is possible that EMMPRINmay
regulate the integrin/laminin association and in doing so, regulate
basement membrane formation, cell adhesion, MMP induction,
chemotaxis and proliferation. It is shown that within cultured insect
cells, EMMPRIN/integrin interactions are essential for lamellipodia
formation andwithin retinal cells. Disruption of the EMMPRIN–integrin
interaction results in aberrant distribution of organelles, including
mitochondria, nuclei and rough endoplasmic reticulum [39].
There are likely undiscovered binding partners for EMMPRIN.
Recently, platelet glycoprotein VI (GPVI) was shown to be a novel
adhesion receptor for EMMPRIN. Prestimulated human platelet cells
showed signiﬁcantly enhanced rolling (but not enhanced ﬁrm
adhesion) on immobilised EMMPRIN-Fc, and pretreatment with
anti-EMMPRIN or anti-GPVI blocking antibodies signiﬁcantly reduced
this rolling [40].
4. Other Substrates or binding partners of EMMPRIN
EMMPRIN has been shown to associate with various proteins,
resulting in its varied functions. Both the transmembrane and
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protein-protein interactions within the plasma membrane [28].
Cyclophilins are members of the immunophilin family of peptidyl-
prolyl cis–trans isomerases and have been proposed to function as
chaperones and mediators of protein folding [41]. Recently, several
reports implicated cyclophilins as regulators of EMMPRIN surface
expression following the observation that cyclosporine A (CsA),
which binds cyclophilins, adversely affected EMMPRIN surface
expression [42–44]. Aside from their functioning as protein chaper-
ones, cyclophilins alsomediate chemotaxis of neutrophils, eosinophils
and T cells when secreted from cells in response to inﬂammatory
stimuli [42,45–47](Fig. 3A). Recently, EMMPRIN has been identiﬁed as
being essential for cyclophilin-mediated signaling [42,48], wherein
binding of extracellular cyclophilin A to EMMPRIN resulted in the
activation of the ERK pathway and chemotaxis of cells. Interestingly,
the association of cyclophilin A and EMMPRIN is further supported by
ﬁndings that increased levels of cyclophilin A in synovial ﬂuid and
increased EMMPRIN levels on reactive neutrophils in rheumatoid
arthritis patients correlated with the severity of disease [49,50]
(Fig. 3B). Furthermore, cyclophilin A is incorporated into HIV-1
virions and has been shown to play a role in early viral infection
[51,52]. EMMPRIN has been shown to facilitate HIV-1 infection
through its interaction with viral associated cyclophilin A, as
explained later on [53] (Fig. 3C).
Caveolin-1 has been shown to directly associate with the ECII
domain of EMMPRIN. This association begins within the Golgi
apparatus of the cell, with caveolin-1 speciﬁcally binding to and
escorting the lower glycosylated forms of EMMPRIN to the plasma
membrane, thus preventing the formation of the self-aggregating,
highly glycosylated species of EMMPRIN which is known to be
responsible for MMP production [34]. Caveolin-1 is a negative
regulator of EMMPRIN, wherein the direct association of Cav-1 with
the second Ig domain of EMMPRIN was found to decrease EMMPRIN
clustering [54]. This hypothesis was supported by the generation of an
EMMPRIN mutant lacking the second Ig domain, which was incapable
of associating with caveolin-1, as well as following the RNAi
knockdown of caveolin-1, both of which resulted in impaired MMP
production.Fig. 3. EMMPRIN interactionwith cyclophillin in disease. EMMPRIN interacts with cyclophillin
to ECM, and osteopontin (OPN) binding that then mediates MMP-2 activation and secretioIn breast cancer cells, thrombin is shown to cleave osteopontin
[55]; the cleaved osteopontin product is shown to bind to cyclophilin
C and to EMMPRIN (Fig. 3D). This in turn activates the Akt1 and 2
pathways, eventually resulting in MMP-2 activation and release from
breast cancer cells [55]. It is reported that EMMPRIN stimulates
hyaluronan production by colon carcinoma and mammary carcinoma
cells [56] and that the effect of EMMPRIN on anchorage-independent
growth is dependent on hyaluronan. Furthermore, EMMPRIN stimu-
lates cell survival pathway signaling in a hyaluronan-dependent
manner. These substrate interactions in part contribute to the
complexity associated with the functions of EMMPRIN.
5. EMMPRIN null mice
EMMPRIN null mice are rarely born due to the embryonic loss
around the time of implantation. It is estimated that only about 30% of
embryos are born, of which 50% of these surviving pups die of
interstitial pneumonia within the ﬁrst week of life [57]. Both males
and females EMMPRIN null homozygotes are sterile, with impaired
spermatogenesis observed in males, and the failure of fertilization and
implantation in female mice [57,58]. Retinal degeneration leading to
dysfunction is also detected in EMMPRIN null mice [17,59]. Only the
two above phenotypes are a direct result of the lack of the bsg gene,
the other observed phenotypes are attributed to linkage disequilib-
rium [60]. Additionally, EMMPRIN null mice show various disorders
related to neural behavior such as poor performance in learning and
memory [61], decreased sensitivity to irritating odors [62], and
increased sensitivity to electric foot shock [61]. Moreover, EMMPRIN
is expressed in the normal CNS and EMMPRIN null mice have several
behavioral and sensory defects [61].
6. A role for EMMPRIN in disease states including of the CNS
Due to its MMP inducing capability EMMPRIN is a candidate for
early upstream regulation of various diseases including tumors and
inﬂammatory diseases, not all of which involve MMPs. EMMPRIN has
been shown to play a role in leukocyte activation and migration,
wherein circulating immune cell populations (including activated T(cyp) A, B and C to result in immune cell chemoattraction in arthritis and HIV, adhesion
n.
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highly express EMMPRIN [63]. The mRNA pool from activated T cells
revealed a 3.75-fold increase in EMMPRIN transcription [64]. Aside
from leukocyte activation, EMMPRIN augments tissue repair and
remodeling [65] and thus is a key player in various major diseases.
Low oxygen conditions exist in the brain during a stroke and
during these conditions of hypoxia and ischemia, cells within the
tissues become dependent upon glycolysis for their energy metabo-
lism. Lactic acid, a byproduct of glycolysis, is transported by the
association of EMMPRIN and lactate transporters MCT-1 and MCT-4
[28,66]. Upregulation of MCT and EMMPRIN expression is reported
under ischemic conditions in both neuronal and cardiac cells [67,68].
As well, EMMPRIN in conjunction with cyclophilin A has been
reported to protect neurons from oxidative stress and ischemia [69].
Although the EMMPRIN/cyclophilin A association and related signal-
ing may provide protection to neurons from ischemic damage, the
induction of MMPs through increased EMMPRIN expression may
promote ischemic related pathology by increasing tissue destruction.
Alzheimer's disease is a neurodegenerative disease characterized
by the errant production of amyloid β peptides that is believed to lead
to the formation of the characteristic amyloid plaques and neuroﬁ-
brillary tangles within the neocortical and subcortical regions of the
brain resulting in disease pathology. The γ secretase complex
regulates production of these amyloid β peptides (reviewed in
[70,71]. Recently, EMMPRINwas shown to be a regulatory component
of the γ secretase complex [71]. Depletion of EMMPRIN from the γ
secretase complex by utilizing siRNA in cell lines resulted in an
increase in amyloid β peptide production but had no effect on the
expression levels of other complex components or complex substrates
suggesting that EMMPRIN may regulate γ secretase activity [71] in
Alzheimer's disease.
Systemic lupus erythematosus (SLE) is a prototypical systemic
autoimmune disease, characterized by T and B cell dysfunctions and
many abnormalities of intracellular signaling pathways, including the
enhanced secretion of MMP-9 by PBMCs. Upon examination,Fig. 4. Speciﬁc activities of EMMPRIN help mediate the inﬁltration of leukocytes into the C
EMMPRIN may play multiple roles. In the periphery, it may alter cell activation and polarizat
and within the CNS itself it may alter CNS pathology via its MMP inducing function.EMMPRIN was overexpressed on CD3+ T lymphocytes from SLE
patients when compared with CD3+ T lymphocytes from healthy
donors. Monoclonal anti-EMMPRIN antibodies, were able to inhibit
activation of T lymphocytes from SLE patients [72], suggesting a role
for EMMPRIN in SLE pathology.
Cyclophilin A incorporation into the virions of HIV-1 is shown to be
signiﬁcantly enhanced in the early steps of HIV-1 infection [73]. Virus-
associated cyclophilin A is shown to co-immunoprecipitate with
EMMPRIN from infected cells and blocking antibodies to EMMPRIN
inhibited HIV-1 entry as evidenced by the delay in translocation of the
HIV-1 core proteins from themembrane and inhibition of viral reverse
transcription. The interaction between HIV-1-associated cyclophilin A
and EMMPRIN on target cells signiﬁcantly enhances infection by HIV-
1 [73](Fig. 3D). These results suggest that HIV-1 entry depends on an
interaction between virus-associated cyclophilin A and EMMPRIN on
a target cell, and EMMPRIN, therefore, appears to be a cofactor that
mediates activity of virus-associated cyclophilin A and is required for
efﬁcient infection by HIV-1. EMMPRIN is also shown to enhance HIV-1
replication in a signaling-independent fashion through speciﬁc events
mediated by the cytoplasmic domain of the protein [73].
7. EMMPRIN in multiple sclerosis
There is currently no direct reference to EMMPRIN in the classic
inﬂammatory disease of the CNS, multiple sclerosis (MS). In this
regard, we have recently examined EMMPRIN expression in MS as
well as in an animal model of the disease, experimental autoimmune
encephalomyelitis (EAE) [74]. We show an increase in EMMPRIN
levels in CNS samples from MS patients (Fig. 5 B) where EMMPRIN
levels are upregulated both on endothelial cells (arrow) as well as
cells within the CNS (Fig. 5 B, inset) whereas EMMPRIN staining is
restricted to endothelial cells of blood vessels in healthy controls
(Fig. 5A). In brief, in MS and EAE, MMPs are known to play detrimental
roles, speciﬁcally in the breach of the blood–brain barrier [75] as well
as in the degradation of myelin within the CNS. EMMPRIN is known toNS and the production of neuropathology. In neuroinﬂammatory diseases such as MS,
ion; at the level of the blood–brain barrier, it may augment cell adhesion and migration;
Fig. 5. Increase in EMMPRIN expression in MS CNS inﬂammatory lesions compared to healthy controls. Double immunoﬂuoresence staining reveals EMMPRIN staining (green) to be
restricted to blood vessels (CD31 positive) in healthy control CNS samples (A, 100× magniﬁcation). In MS CNS samples (B, 200× magniﬁcation), EMMPRIN staining is highly
upregulated on endothelial cells of blood vessels (arrow) and also on leukocytes inﬁltrating the CNS (CD45 positive, inset).
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both at the level of the blood–brain barrier in MS and EAE (Fig. 4A), as
well as within the CNS in the MMP mediated myelin destruction
(Fig. 4B). Various other roles for EMMPRIN are possible in autoim-
mune diseases such as MS; EMMPRIN may play an early role in
leukocyte activation and polarization within peripheral lymphoid
organs, as well as within the blood vessels of the CNS, wherein
EMMPRIN interaction with integrins may affect the cell adhesion
crucial in T-cell migration through the blood–brain barrier (Fig. 4A).
The monocarboxylate transporter, MCT-1, is expressed on astro-
cytes. On these cells, MCT-1 transports lactate out of the cells into the
surrounding, providing energy for neighboring cells such as neurons
[28,66]. EMMPRIN has been shown to be crucial in the proper lactate
transport via MCT-1 by astrocytes [76]. In MS and EAE, EMMPRINmay
also play a protective role in the CNS parenchyma, where it binds to
MCT-1 on astrocytes to allow the transport of lactate to the
neighbouring neurons and oligodendrocytes (Fig. 4B). This proposed
function of EMMPRIN is currently being investigated in our laboratory.8. EMMPRIN based therapy
Various anti-EMMPRIN based therapies have been utilized to
target EMMPRIN mediated diseases. In a mouse model of asthmatic
inﬂammation, it was shown that cyclophilins induce EMMPRIN-
dependent chemotaxis of activated CD4+ T cells in vitro. In vivo
treatment with anti-EMMPRIN function blocking antibody signiﬁ-
cantly reduced the accumulation of CD4+ T-cells in lung tissues,
suggesting a novel mechanism whereby asthmatic lung inﬂammation
may be reduced by targeting cyclophilin-EMMPRIN interactions [77].
Utilizing a speciﬁc anti-EMMPRIN function blocking antibody,
Damsker and colleagues [78] demonstrated that pro-inﬂammatory
leukocytes lose their ability to migrate in response to cyclophilin A.
Furthermore, they showed that mice treated with anti-EMMPRIN
antibody reduced the development of collagen-induced arthritis by
N75%, suggesting a role for EMMPRIN in promoting the recruitment of
leukocytes into joint tissues.
Tumor speciﬁc EMMPRIN peptides have been sequenced and
identiﬁed for many years. Some of these are utilized as activity-
blocking peptides (emp#2) in in vitro experiments [79]; and others
such as HAb18G/CD147 (AP-9), constructed against the EC1 domain
of EMMPRIN has been utilized in vitro and in vivo to block EMMPRIN
activity, and speciﬁcally blocking the MMP inducing function of
EMMPRIN [80]. HAb18G/CD147 is shown to be a hepatocellular
carcinoma associated antigen. In hepatocellular carcinoma, iodine
(131I) metuximab (Licartin); a novel 131I-labeled HAb18G/CD147-
speciﬁc monoclonal antibody F(ab')2 fragment, was found to bepharmacologically safe and clinically efﬁcacious in phase I/II trials
[81]. Metuximab injections were shown to be efﬁcient in murine anti-
hepatocellular carcinoma and the humanized (HAb18-huscFv)2-Fc
was shown to be a more efﬁcient antibody fragment with less
immunogenicity and additional roles in cell cytotoxicity [82].
Resveratrol (3,4',5 trihydroxystilbene), a naturally occurring
molecule known as a phytoalexin, is synthesized by plants in response
to attacks by fungi and bacteria; it is also known to possess an array of
cardioprotective effects. Recently, studies have shown resveratrol to
protect against the metabolic changes associated with hypercaloric
diets in mice with induced insulin resistance, hyperglycemia, and
dyslipidemia [83]. Both resveratrol and a PPARγ agonist, pioglitazone,
were recently shown to signiﬁcantly inhibit EMMPRIN expression and
MMP-9 activity in a concentration-dependent manner [84]. The
effects of pioglitazone and resveratrol were reversed by pretreatment
of THP-1 cells with a PPARγ antagonist, GW9662, suggesting that
resveratrolmay down-regulate EMMPRIN andMMP-9 through PPARγ
activation. [84].9. Conclusions
EMMPRIN is an early inducer of MMPs, it has a varied distribution
and binds not only to itself in a homotypic cis pattern, but also to other
ligands such as cyclophilin, MCT-1 and integrins. Binding to these
various partners makes EMMPRIN-mediated functions varied and
accounts for the multiple roles it plays in various diseases. Targeting
EMMPRIN in inﬂammatory diseases may aid in reducing the
destruction caused by inﬁltrating EMMPRIN positive immune cells.References
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